Objective: Single inhaler triple therapy is widely used in Chronic Obstructive Pulmonary Disease (COPD) and asthma. This research aimed to analyze adverse events (AEs ...

PT010 is based on the inhaled corticosteroid budesonide, long-acting muscarinic antagonist (LAMA) glycopyrronium and long-acting beta agonist (LABA) formoterol fumarate, and has been filed for ...

The Spanish COPD guidelines recommend treatment of the mixed COPD–asthma phenotype with ICS and a long-acting bronchodilator (LABD) as a first option to improve lung function, respiratory ...

Trimbow (beclometasone+formoterol+glycopyrronium) combines an inhaled corticosteroid (ICS), a long-acting beta adrenoceptor agonist (LABA) and a long-acting muscarinic antagonist (LAMA ...

Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is a commonly encountered yet loosely defined clinical entity. ACOS accounts for approximately 15–25% of the ...

Data from a new randomized, placebo-controlled trial have demonstrated the efficacy of budesonide in inducing remission of this disease; this study is an important contribution to this field.

Asthma can cause excess mucus buildup in the lungs, leading to chest congestion. It usually worsens when you have a respiratory infection or when your allergies are acting up. However, you can also ...

We have compared the time course of action of fluticasone and budesonide, measuring response as change in the provocative dose of adenosine monophosphate causing a 20% fall in forced expiratory volume ...